(Oslo, April 3, 2023) Medistim ASA (OSE: MEDI) is a niche market leader in
ultrasound technology, headquartered in Oslo, Norway. The company develops and
commercializes medical equipment for use in Cardiac, Vascular, and Transplant
surgery. Today, Medistim announce that they are expanding their market coverage
in China by establishing a direct sales office, opening today. This move is part
of the company's ongoing commitment to providing exceptional service to
customers as well as fulfilling the company's global growth strategy. 

More than 60,000 coronary bypass procedures are performed in China annually and
the number is expected to continue to grow high single digit in the years to
come.  Today, about 70% of these procedures are supported by Medistim's
equipment, which is installed in all the nation's top 10 cardiac surgical
centers.  The company is well positioned to continue its growth by further
expanding the local distributor network and building on the ongoing conversion
from devices with Transit Time Flow Measurement (TTFM) technology only, to
devices combining TTFM and High-Frequency Ultrasound (HFUS). In addition, a
large market within Vascular and Transplant surgery provides opportunities for
further growth. 

The new subsidiary, Medistim (Guangzhou) Medical Technology Co., Ltd., is a
Wholly Foreign Owned Enterprise (WFOE) by Medistim ASA. It is located in
Guangzhou in the Greater Bay Area, a region with a vision to become a leader
within healthcare technology. Guangzhou is a major regional business center and
hosts the Norwegian Consulate General office for South China.  

Medistim take the opportunity to acknowledge and appreciate the longstanding and
successful collaboration with Pacific Medical Systems Ltd (PMS) as a
distribution partner in Greater China and Southeast Asia since 2004. PMS and its
distribution network have established the Medistim brand from scratch to become
the recognized standard of care in CABG surgery in China that it is today. PMS
will remain a close partner for Medistim as a distributor in other Asian
markets. 

"We are excited to take this step forward with our direct office in Guangzhou
and strengthen our relationship with our customers in China," says Medistim
President and CEO Kari E. Krogstad. "China represents a significant growth
opportunity, and it is time to strengthen our presence in this key market.  With
our continued collaboration with PMS, 2023 will be a year of transition, as we
build our own organization and develop the customer relationships.  Over the
next years, this change will help the company to further expand market presence
and strengthen our position as a leader in the industry." 

"We believe that a world-leading Med Tech company like Medistim will prosper
with the opportunities China can provide with their own subsidiary and provide
new business development opportunities in this strong and growing market," says
Hege Araldsen, Consul General, Norwegian Consulate General Guangzhou. 

About Medistim: 

Medistim was established in 1984 and has a track record of profitable growth
over the past 20 years. The company is a pioneer within its segment and
continues to invest in new product development. Medistim has wholly owned
subsidiaries with sales organizations in the USA, Canada, China, Germany, the
UK, Spain, Denmark, and Norway, in addition to around 60 distributors in Europe,
Asia, the Middle East, Africa, and South America. 

For more information, visit the Medistim home page:  www.medistim.com  

For more information, contact:  
President and CEO, Kari E. Krogstad, Medistim ASA 
Tel: + 47 918 38 110   
Email: kari.krogstad@medistim.com  
 
CFO, Thomas Jakobsen, Medistim ASA 
Tel: + 47 906 59 940   
Email: thomas.jakobsen@medistim.com